Related references
Note: Only part of the references are listed.Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Tuba N. Gide et al.
CLINICAL CANCER RESEARCH (2018)
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
Daniel N. Cagney et al.
NEURO-ONCOLOGY (2017)
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy
Helena Cirenajwis et al.
ONCOTARGET (2015)
Cancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma
Jian Guan et al.
SCIENTIFIC REPORTS (2015)
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Lucia B. Jilaveanu et al.
CLINICAL CANCER RESEARCH (2015)
Prominin-2 expression increases protrusions, decreases caveolae and inhibits Cdc42 dependent fluid phase endocytosis
Raman Deep Singh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome
Goran Jonsson et al.
CLINICAL CANCER RESEARCH (2010)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
Share Paper
